Gene and Cell Therapy – News and Features

Researchers have tested a new way of treating childhood brain cancer by combining two medicines in lab studies, finding that combination therapy could be more effective.

New library of 400 immune-related factors and screening platform can find precise recipes for reprogramming accessible cells into rare immune cells, including NK cells, advancing immunotherapies beyond caner.

Rice University researchers created CLASSIC, a platform that builds vast libraries of genetic circuits and links each full DNA sequence to its output in human cells. CLASSIC predicts circuit performance across untested designs.

A new "double-pronged" CAR T immunotherapy recognizes two distinct features of multiple myeloma to destroy the cancer more effectively.

Researchers at the University of British Columbia developed a reliable method to produce helper T cells from stem cells by precisely tuning Notch signaling, enabling scalable, off-the-shelf immune cell therapies for cancer and other diseases.

A newly developed immune cell atlas uses insights into how the immune system interacts with cancer cells to determine how aggressive a patient’s multiple myeloma is likely to be.

A new analysis suggests most Alzheimer’s cases depend on the APOE gene, making it a major target for prevention and treatment. The analysis suggests APOE plays a far larger role than previously recognized.

In this interview, Claudio Panzarella and Angelo Raggioli discuss advances in ReiThera's viral vector platforms and the advantages they offer.

This article explores advances in both in vivo and ex vivo CAR T-cell therapies and discusses strategic development considerations that can reduce uncertainty and accelerate decision-making.

Technology Networks spoke with Dr. David James, professor of bioprocess engineering at the University of Sheffield and co-founder and chief scientific officer at SynGenSys, to learn more about the importance of synthetic promoter design.